Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial

Comparison of Paclitaxel-, Sirolimus-, and Zotarolimus-Eluting Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction and Metabolic Syndrome

“…The SORT OUT III study, however, showed that SES is superior to ZES for low-risk patients receiving routine clinical care during an 18-month follow-up. 31 The discrepancy of the outcomes between the present study and SORT OUT III study might be due to enrolled patient characteristics and the clinical setting. Stent thrombosis is a dramatic clinical event associated with MI and frequent mortality.…”

Randomized Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients Treated With Percutaneous Coronary Intervention

“…However, the first commercially available secondgeneration drug-eluting stent, the zotarolimus-eluting Endeavor stent, did not appear superior to the sirolimus-eluting stent in routine practice. 6 The next second-generation drugeluting stent, the everolimus-eluting stent, proved superior to the paclitaxel-eluting stent, with a lower rate of stent thrombosis, myocardial infarction, and target vessel revascularization 7 and reduced angiographic late loss. 8 In a recent allcomer trial of second-generation drug-eluting stents, the zotarolimus-eluting stent proved noninferior to the everolimus-eluting stent despite a higher 1-year rate of definite stent thrombosis in the zotarolimus group.…”

Single-centre all-comers registry reveals promising long-term clinical results of the Endeavor<sup>TM</sup>-Stent

“…Mauri et al published a meta-analysis including 6 randomized trials comparing the Endeavor TM -Stent to BMS with more than 2.100 patients: After 5 years the TLR-rate for the Endeavor TM -Stent was 7.0% (vs. 16.5% for the BMS) and the overall mortality rate 5.9% (vs. 7.6% for BMS) [24]. The SORT OUT III trial revealed an 18-month TLR rate of 6% (vs. 2% for the sirolimuseluting stent), however it did not really represent an "allcomers" trial, as more than 50% of the eligible patients had not been included [23]. Recently published data from the KOMER AMI trial, comparing the Endeavor TM -Stent with paclitaxel-and sirolimus-eluting stents in acute STelevation myocardial infarction, reported a target vessel failure of 15% for the Endeavor TM -Stent after two years, which did not differ significantly from the other stents [25].…”

“…Recently, it has been proven, that the Endeavor TM -Stent showed better endothelial strut coverage even in myocardial infarction in comparison to other DES [32][33][34]. However, the SORT OUT III trial revealed a low (1%) but significantly higher rate of definite stent-thrombosis after nine months in comparison to sirolimus-eluting stents [23].…”